In the wake of Cronos group (NASDAQ:CRON; TSXV:CRON) becoming the first Canadian licensed producer (LP) to offer its common stock in the Nasdaq Global Market, a selection of fellow LPs have since announced their intentions to also join premier US stock exchanges soon enough.

Bruce Linton, CEO of Canopy Growth (TSX:WEED) said during a public event in early March that his company was already preparing for a Nasdaq listing when it became involved with an investment deal from alcohol producer Constellation Brands (NYSE:STZ).

The Nasdaq listing for cannabis companies will require these companies do not hold assets in the US that involve any physical interaction with marijuana.

“The Nasdaq is doing a great job not allowing people to list who break federal laws and that’s a place where we should list in due course,” Linton said.

As reported by the Financial Post, Beacon Security analyst Vahan Ajamian wrote in a note that he expected the Canopy US listing to take place in the second quarter of the 2018 fiscal year.

Not to be left behind, Aurora Cannabis (TSX:ACB; OTC:ACBFF), which already lists on the OTCQX Best Market, announced it is also exploring the option to offer its stock on other exchanges.

“We’ll look at all exchanges, we’ll look at New York Stock Exchange,” Terry Booth, CEO of Aurora told Bloomberg.

Cronos trying to showcase legal cannabis market

After launching its stock on the Nasdaq, Mike Gornstein, CEO of Cronos said the entire industry is trying to raise awareness of the burgeoning legal cannabis industry.

“We did have a number of investors we’d speak to in the US that would ask ‘is it even legal to invest in a Canadian cannabis company?’ And by listing on the Nasdaq we are able to help that,” Gornstein told BNN.

Gornstein added part of the company’s motive behind launching on the Nasdaq relates to the possibility of entering the US market once it becomes federally legal and attracting American investors ahead of time.

Cronos officially launched its Nasdaq stock on March 6. Since then its share price has gone down 10.99 percent. At market close on Monday (March 12) market closure, Cronos finished at $8.79 signifying a 5.63 decrease and a $0.53 loss per share.

Investor Takeaway

Spearheaded by Cronos, the move to offer stock in the premier US exchanges offers a chance at legitimacy for the entire cannabis industry and–as repeatedly explained by executives–the type of investors available on these exchanges.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

All five flavours of the Company’s KOIOS™ nootropic beverage product are now being carried by Jensen’s, a regional supermarket chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. This placement of KOIOS™ follows several other recent placements of the Company’s beverage products in regional supermarket chains across the United States as part of a strategy to passively build market share in specific geographical areas.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that the full range of five flavours of its KOIOS ™ nootropic beverages can now be purchased at all grocery stores operated by Jensen’s Foods (“Jensen’s”), a long-established family-owned grocery chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. In a press release dated February 19, 2021 the Company announced another chain-wide placement of KOIOS ™ nootropic beverages on the west coast of the United States with Market of Choice in Oregon. With this placement of KOIOS ™ in Jensen’s supermarkets, the Company’s beverage products are now carried in approximately 180 retail stores on the west coast, out of a total of more than 4,000 retail stores nationwide.

Keep reading... Show less

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less

As Canadian operators race to strengthen their positions in the cannabis landscape, are international pursuits outside North America still top of mind?

The role that mergers and acquisitions (M&A) have played in the expansion of Canadian companies across the globe has been monumental for the growth of the cannabis industry. Now the space has reached a critical point as the demands of the US market increase.

Keep reading... Show less

It’s been just over a year since recreational cannabis was legalised in the Australian Capital Territory (ACT), home to the nation’s capital city of Canberra.

Announced on September 25, 2019, and brought into effect on January 31, 2020, the rules make it legal to possess and personally use small amounts of cannabis.

Keep reading... Show less

Pac Roots Cannabis Corp. (CSE: PACR) (“PacRoots” or the “Company”), announces the closing of its previously announced non-brokered private placement (see press release dated January 25, 2021).

Aggregate gross proceeds of $1,340,685.90 were raised through the issuance of 7,448,255 units (each a “Unit”). Each Unit consists of one common shares and one share purchase warrant. Each warrant is exercisable at a price of $0.30 per share until February 23, 2024.

Keep reading... Show less